

AMENDMENT TO THE CLAIMS:

The following claim listing will replace all previous listings of the claims:

1. (Currently amended) An isolated, synthetic or recombinant χ -conotoxin peptide comprising the following sequence of amino acids:

Xaal Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3
where Xaal is a N-terminal pyroglutamate (pGlu) or D-pyroglutamate (DpGlu) residue; and Xaa2 is Asn or a deletion; ~~or such a sequence in which~~ optionally one or more Cys is replaced with its corresponding D-amino acid, ~~and/or~~ optionally Pro has been replaced with 4-hydroxyproline, ~~and/or~~ and optionally Tyr is substituted with 4-methoxy tyrosine; or a salt or amide thereof.

2. (Currently amended) The peptide according to claim 1 consisting of the following sequence of amino acids:

Xaal Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3
where Xaal is a N-terminal pyroglutamate (pGlu) or D-pyroglutamate (DpGlu) residue; and Xaa2 is Asn or a deletion; ~~or such a sequence in which~~ optionally one or more Cys is replaced with its corresponding D-amino acid, ~~and/or~~ optionally Pro has been replaced with 4-hydroxyproline, ~~and/or~~ and optionally Tyr is substituted with 4-methoxy tyrosine; or a salt or amide thereof.

3. (Previously presented) The peptide according to claim 1 wherein Pro has been replaced with 4-hydroxyproline.

4. (Currently amended) The peptide according to claim 1 having the following sequence of amino acids

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys SEQ ID NO. 4
Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Xaa5 SEQ ID NO. 5;
Xaal Gly Val Cys Cys Gly Xaa4 Lys Leu Cys His Xaa3 Cys SEQ ID NO. 6;
Xaal Asn Gly Val Cys Cys Gly Xaa4 Lys Leu Cys His Xaa3 Cys SEQ ID NO. 7

Xaal Asn Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys SEQ ID NO. 8

or

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys-OH SEQ ID NO. 9;

where Xaal is N-terminal pGlu, Xaa3 is 4-hydroxyproline, Xaa4 is 4-methoxy tyrosine, Xaa5 is D-cysteine and -OH indicates a free acid C terminal.

5. (Previously presented) The peptide according to claim 1 having the following sequence of amino acids

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys-OH SEQ ID NO. 10

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys SEQ ID NO. 11

where Xaal is DpGlu, Xaa3 is 4-hydroxyproline and -OH indicates a free acid C terminal.

6. (Previously presented) A composition comprising the peptide of any one of claims 1 to 5 together with pharmaceutically acceptable carrier or diluent.

7. (Original) The composition of claim 6 further comprising one or more other active agents.

8-10. (Canceled)

11. (Canceled) ~~A method for the treatment or prophylaxis of urinary or cardiovascular conditions or diseases, or mood disorders, or for the treatment or control of acute, chronic and/or neuropathic pain, migraine or inflammation in a mammal comprising administering to the mammal an effective amount of an isolated, synthetic or recombinant χ -conotoxin peptide of any one of claims 1-5 or 15-16.~~

12-14. (Canceled)

15. (Previously presented) An isolated, synthetic or recombinant χ -conotoxin peptide or a salt, ester or amide thereof, wherein said peptide comprises the following amino acid sequence:

pGlu Gly Val Cys Cys Gly Tyr Lys Leu Cys His Hyp Cys (SEQ ID NO: 4).

16. (Previously presented) An isolated, synthetic or recombinant amidated χ -conotoxin peptide, wherein said peptide comprises the following amino acid sequence:

pGlu Gly Val Cys Cys Gly Tyr Lys Leu Cys His Hyp Cys (SEQ ID NO: 4),
and wherein the C-terminal Cys residue is amidated.

17. (Withdrawn and currently amended) A method for the treatment or control of acute, chronic and/or neuropathic pain, migraine or ~~inflammation~~inflammatory pain in a mammal comprising administering to the mammal an effective amount of an isolated, synthetic or recombinant χ -conotoxin peptide of any one of claims 1-5 or 15-16.

18. (Withdrawn and currently amended) The method of claim ~~17~~22, wherein the neuropathic pain is associated with surgery (post operative pain), gut, cancer, diabetic, phantom limb, or nerve damage, ~~inflammatory pain and peripheral nerve associated pain.~~

19. (Withdrawn and currently amended) The method of claim 17, wherein the peptide is administered substantially simultaneously or sequentially with other agents useful in the treatment of said ~~conditions, diseases or disorders, or said pain~~[[,]] or migraine or inflammation.

20. (Canceled) The method of claim 11, wherein the neuropathic pain is associated with surgery (post operative pain), gut, cancer, diabetic, phantom limb, nerve damage, inflammatory pain and peripheral nerve associated pain.

21. (Canceled) The method of claim 11, wherein the peptide is administered substantially simultaneously or sequentially with other agents useful in the treatment of said conditions, diseases or disorders, or said pain, migraine or inflammation.

22. (New) The method of claim 17, wherein said method is for the treatment and control of neuropathic pain.